

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

PC 02120

315677

<p>Licensee</p> <p>1. St. Francis Medical Center</p> <p>2. 211 St. Francis Drive Cape Girardeau, MO 63703</p>	<p>In accordance with the letter dated August 25, 2006,</p> <p>3. License number 24-00158-03 is amended in its entirety to read as follows:</p> <p>4. Expiration date September 30, 2015</p> <p>5. Docket No. 030-02269 Reference No.</p>
---	--

<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Iodine-125 permitted by 10 CFR 35.400</p> <p>E. Any byproduct material permitted by 10 CFR 35.500</p> <p>F. Any byproduct material permitted by 10 CFR 31.11</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Sealed sources (Medi-Physics OncoSeed Model 6711 and EchoSeed Model 6733)</p> <p>E. Sealed sources (North American Scientific Model No. 3601 or DuPont Pharma Model No. NES 8412)</p> <p>F. Prepackaged Kits</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. As needed (not to exceed one curie of iodine-131)</p> <p>D. As needed</p> <p>E. 600 millicuries</p> <p>F. As needed</p>
---	--	---

<p>9. Authorized Use:</p> <p>A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.</p> <p>B. Any imaging and localization study permitted by 10 CFR 35.200.</p> <p>C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.</p>

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
24-00158-03

Docket or Reference Number
030-02269

Amendment No. 59

- D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.
- E. Medical use described in 10 CFR 35.500 in devices which have been evaluated and approved for licensing purposes by the U.S. Nuclear Regulatory Commission or an Agreement State.
- F. In vitro studies.

CONDITIONS

- 10. Licensed material may be used or stored at the licensee's facilities located at 211 St. Francis Drive, Cape Girardeau, Missouri.
- 11. The Radiation Safety Officer for this license is Mark Gates, M.D.
- 12. Licensed material is only authorized for use by, or under the supervision of:
 - A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
 - B. The following individuals are authorized for medical use as indicated:

Authorized Users

Material and Use

Mike J. Brown, M.D.	10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for treatment of thyroid carcinoma), 35.500 and 31.11.
Paul C. Horn, M.D.	10 CFR 35.100, 35.500 and 31.11.
Willeford J. Stoecker, M.D.	10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for treatment of thyroid carcinoma) and 35.500.
Craig W. Williams, M.D.	10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for treatment of thyroid carcinoma) and 35.500.
Kenneth Retter, M.D.	10 CFR 35.200, limited to cardiovascular clinical procedures and 35.500.
Tappan Roy, M.D.	10 CFR 35.300 and iodine-125 in 10 CFR 35.400.
Mark Lewis Pfautsch, D.O.	10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for treatment of thyroid carcinoma) and 35.500.
William Scott Campbell, Jr., M.D.	10 CFR 35.100, 35.200 (excluding generators), 35.300 (excluding iodine-131 for treatment of thyroid carcinoma) and 35.500.
Mark L. Gates, M.D.	10 CFR 35.100, 35.200, 35.300 and 35.500.
David R. Anderson, M.D.	10 CFR 35.100, 35.200, 35.300 and 35.500.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
24-00158-03

Docket or Reference Number
030-02269

Amendment No. 59

- George A. Pjura, M.D. 10 CFR 35.100, 35.200, 35.300 and 35.500.
- Theodore R. Swartz, M.D. 10 CFR 35.100, 35.200 (excluding xenon-133) and 35.500.
- David A. Law, M.D. 10 CFR 35.200 (excluding generators, xenon-133, aerosols, sodium iodide I-125 and sodium iodide I-131), limited to cardiovascular clinical studies.
- Bryan S. Beck, M.D. 10 CFR 35.200 (excluding generators, xenon-133, aerosols, sodium iodide I-125 and sodium iodide I-131), limited to cardiovascular clinical studies.
- Jagannohan R. Alinani, M.D. 10 CFR 35.100, 35.200, 35.500 and 31.11.
- Rajinder M. Gulati, M.D. 10 CFR 35.100, 35.200, 35.300, 35.500 and 31.11.
- Tom Brumitt, M.D. 10 CFR 35.100, 35.200 and 35.300 (excluding iodine-131 for treatment of thyroid carcinoma).
- James Borders, M.D. 10 CFR 35.100, 35.200 and 35.500.
- Huan Nguyen, M.D. 10 CFR 35.100, 35.200 and 35.500.
- Christopher Russell, M.D. 10 CFR 35.100, 35.200 and 35.500.
- Raleigh F. Johnson, III, M.D. 10 CFR 35.100, 35.200 and 35.500.
- Andrew E. West, M.D. 10 CFR 35.100, 35.200 and 35.500.
- Patricia MacFarlane, M.D. 10 CFR 35.100, 35.200 and 35.500.
- Cedric Strange, M.D. 10 CFR 35.100, 35.200 and 35.500.

COMMISSION

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

14. The licensee may transport licensed material or deliver licensed material to a carrier for transport in accordance with the provisions of Title 10, Code of Federal Regulations, Part 71, "Packaging of Radioactive Material for Transport and Transportation of Radioactive Material Under Certain Conditions."


**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
24-00158-03

Docket or Reference Number
030-02269

Amendment No. 59

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated March 29, 2005 (excluding references to QMP and written directives); and,
 - B. Letters dated March 16, 2005, September 23, 2005 (includes facsimile-transmitted document also dated September 23, 2005) and **August 25, 2006**.



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

OCT 10 2006

Date _____

By *Toye L. Simmons*
 Toye L. Simmons
 Materials Licensing Branch
 Region III